Close

Maxim Group Reiterates Buy Rating and $9 PT on Intec Pharma (NTEC) Following Ph1 Trial Initiation of CBD/THC Using the Accordion Delivery System

March 24, 2017 7:35 AM EDT Send to a Friend
Maxim Group analyst Jason Kolbert reiterates Buy rating and $9 price target on Intec Pharma Ltd. (NASDAQ: NTEC), as the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login